These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31031466)

  • 41. Comparison between drug screening by immunoassay and ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry in post-mortem urine.
    Sundström M; Pelander A; Ojanperä I
    Drug Test Anal; 2015 May; 7(5):420-7. PubMed ID: 24953563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-matrix assay of cortisol, cortisone and corticosterone using a combined MEPS-HPLC procedure.
    Saracino MA; Iacono C; Somaini L; Gerra G; Ghedini N; Raggi MA
    J Pharm Biomed Anal; 2014 Jan; 88():643-8. PubMed ID: 24231793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine.
    Wasan AD; Michna E; Janfaza D; Greenfield S; Teter CJ; Jamison RN
    Pain Med; 2008 Oct; 9(7):918-23. PubMed ID: 18616432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of the 12-Month Stability of Dried Blood and Urine Spots Applying Untargeted UHPLC-MS Metabolomic Assays.
    Palmer EA; Cooper HJ; Dunn WB
    Anal Chem; 2019 Nov; 91(22):14306-14313. PubMed ID: 31618007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determination of morphine in urine by solid-phase immunoextraction and high-performance liquid chromatography with electrochemical detection.
    Rashid BA; Aherne GW; Katmeh MF; Kwasowski P; Stevenson D
    J Chromatogr A; 1998 Feb; 797(1-2):245-50. PubMed ID: 9542117
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Agreement between urinalysis and self-reported drug use.
    Hamid R; Deren S; Beardsley M; Tortu S
    Subst Use Misuse; 1999 Sep; 34(11):1585-92. PubMed ID: 10468109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urinary concentrations of morphine after the administration of herbal teas containing Papaveris fructus in relation to doping analysis.
    Van Thuyne W; Van Eenoo P; Delbeke FT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Mar; 785(2):245-51. PubMed ID: 12554137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of morphine and codeine in samples adulterated with Stealth.
    Cody JT; Valtier S; Kuhlman J
    J Anal Toxicol; 2001 Oct; 25(7):572-5. PubMed ID: 11599602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interpreting Urine Drug Screen Results in the Context of Poppy Seed Use.
    Pearson AC; Eldrige JS; Hooten WM
    Mayo Clin Proc; 2015 Dec; 90(12):1734-5. PubMed ID: 26653302
    [No Abstract]   [Full Text] [Related]  

  • 50. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Family physicians' proficiency in urine drug test interpretation.
    Reisfield GM; Webb FJ; Bertholf RL; Sloan PA; Wilson GR
    J Opioid Manag; 2007; 3(6):333-7. PubMed ID: 18290585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Considerations in the interpretation of urine analyses in suspected opiate intoxications.
    Levine B; Smialek JE
    J Forensic Sci; 1998 Mar; 43(2):388-9. PubMed ID: 9544548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experience with a urine opiate screening and confirmation cutoff of 2000 ng/mL.
    Fraser AD; Worth D
    J Anal Toxicol; 1999 Oct; 23(6):549-51. PubMed ID: 10517566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In-vial dried urine spot collection and processing for quantitative analyses.
    Dvořák M; Maršala R; Kubáň P
    Anal Chim Acta; 2023 May; 1254():341071. PubMed ID: 37005033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A leader in the field...
    DeVito RA
    J Opioid Manag; 2015; 11(1):6. PubMed ID: 25881374
    [No Abstract]   [Full Text] [Related]  

  • 56. Using urine drug testing to support healthy boundaries in clinical care.
    Heit HA; Gourlay DL
    J Opioid Manag; 2015; 11(1):7-12. PubMed ID: 25750160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The implications of urine drug testing in pain management.
    Vadivelu N; Chen IL; Kodumudi V; Ortigosa E; Gudin MT
    Curr Drug Saf; 2010 Jul; 5(3):267-70. PubMed ID: 20394568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ONTRAK TESTCUP: a novel, on-site, multi-analyte screen for the detection of abused drugs.
    Towt J; Tsai SC; Hernandez MR; Klimov AD; Kravec CV; Rouse SL; Subuhi HS; Twarowska B; Salamone SJ
    J Anal Toxicol; 1995 Oct; 19(6):504-10. PubMed ID: 8926746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in Urine Drug Screen Sensitivity in Adolescent Opioid Presentations to the Emergency Department.
    Sidlak A; Dhaliwal M
    Pediatr Emerg Care; 2024 Sep; 40(9):650-653. PubMed ID: 38950407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of a direct high-capacity target screening approach for urine drug testing using liquid chromatography-time-of-flight mass spectrometry.
    Saleh A; Stephanson NN; Granelli I; Villén T; Beck O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Nov; 909():6-13. PubMed ID: 23153637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.